Skip to content
DataLookout
Menu

NCT07222969

A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)

At risk: Primary completion moved 5 months later, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified Show 5 more changesShow less
    • Eligibility criteria expanded, about 109 words
    • Primary completion pushed from Apr 30, 2027 to Sep 30, 2027
    • Study completion pushed from Jun 30, 2027 to Dec 30, 2027
    • Study sites: 2 to 4
    • Secondary endpoints: 9 to 3
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date changed from estimate of Oct 30, 2025 to Jan 12, 2026
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence of treatment-related adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, and DLTs
Timeframe: From the first drug administration to 150 days after the last drug administration
MTD and/or RP2D based on the incidence and nature of DLTs
Timeframe: From the first drug administration to the last day of DLT observation period

Secondary (3)

Pharmacokinetic parameters
Preliminary anti-tumor activity
Immunogenicity parameters

Arms and interventions

VIB305 for Injection in Cohort 1Experimental

VIB305 for Injection does in Cohort 1 according to protocol

VIB305 for Injection in Cohort 2Experimental

VIB305 for Injection does in Cohort 2 according to protocol

VIB305 for Injection in Cohort 3Experimental

VIB305 for Injection does in Cohort 3 according to protocol

VIB305 for Injection in Cohort 4Experimental

VIB305 for Injection does in Cohort 4 according to protocol

VIB305 for Injection in Cohort 5Experimental

VIB305 for Injection does in Cohort 5 according to protocol

VIB305 for Injection in Cohort 6Experimental

VIB305 for Injection does in Cohort 6 according to protocol

Drugs: VIB305 for Injection

Sites

4 sites in 2 countries

China 3, Australia 1